Gt Biopharma Stock Performance
| GTBP Stock | USD 2.74 0.06 2.14% |
On a scale of 0 to 100, GT Biopharma holds a performance score of 7. The company owns a Beta (Systematic Risk) of -0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning GT Biopharma are expected to decrease at a much lower rate. During the bear market, GT Biopharma is likely to outperform the market. Please check GT Biopharma's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether GT Biopharma's current price history will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in GT Biopharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, GT Biopharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (8.20) | Five Day Return 12.9 | Year To Date Return (63.40) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:30 | Dividend Date 2017-08-21 | Last Split Date 2024-02-05 |
1 | GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 09/26/2024 |
2 | Acquisition by Urban Alan Louis of 23335 shares of GT Biopharma at 2.11 subject to Rule 16b-3 | 10/17/2024 |
3 | Disposition of 12447 shares by Bristol Investment Fund Ltd of GT Biopharma at 1.25 subject to Rule 16b-3 | 10/25/2024 |
4 | Acquisition by Berk Gregory of 50000 shares of GT Biopharma at 6.33 subject to Rule 16b-3 | 10/31/2024 |
5 | Acquisition by Berk Gregory of 278058 shares of GT Biopharma subject to Rule 16b-3 | 11/13/2024 |
6 | GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewswire | 11/14/2024 |
7 | GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com | 11/27/2024 |
8 | GT Biopharma Stock Rating Upgraded by Roth Capital | 12/03/2024 |
| Begin Period Cash Flow | 5.7 M |
GTBP |
GT Biopharma Relative Risk vs. Return Landscape
If you would invest 218.00 in GT Biopharma on September 13, 2024 and sell it today you would earn a total of 56.00 from holding GT Biopharma or generate 25.69% return on investment over 90 days. GT Biopharma is currently generating 0.4839% in daily expected returns and assumes 5.0898% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than GTBP, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GT Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GT Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GT Biopharma, and traders can use it to determine the average amount a GT Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0951
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GTBP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.09 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average GT Biopharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding it to a well-diversified portfolio.
GT Biopharma Fundamentals Growth
GTBP Stock prices reflect investors' perceptions of the future prospects and financial health of GT Biopharma, and GT Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GTBP Stock performance.
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (3.78 M) | ||||
| Shares Outstanding | 2.23 M | ||||
| Price To Book | 3.24 X | ||||
| EBITDA | 5.98 M | ||||
| Net Income | (7.6 M) | ||||
| Cash And Equivalents | 23.73 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 58 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 5.41 X | ||||
| Cash Flow From Operations | (8.85 M) | ||||
| Earnings Per Share | (7.39) X | ||||
| Market Capitalization | 6.23 M | ||||
| Total Asset | 14.11 M | ||||
| Retained Earnings | (682.07 M) | ||||
| Working Capital | 7.42 M | ||||
About GT Biopharma Performance
Assessing GT Biopharma's fundamental ratios provides investors with valuable insights into GT Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GT Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 61.05 | 86.22 | |
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (1.82) | (1.91) | |
| Return On Assets | (0.54) | (0.51) | |
| Return On Equity | (1.02) | (1.07) |
Things to note about GT Biopharma performance evaluation
Checking the ongoing alerts about GT Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GT Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GT Biopharma had very high historical volatility over the last 90 days | |
| GT Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: GT Biopharma Stock Rating Upgraded by Roth Capital |
- Analyzing GT Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GT Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining GT Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GT Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GT Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GT Biopharma's stock. These opinions can provide insight into GT Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.